Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 2.48
EW's Cash to Debt is ranked higher than
72% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. EW: 2.48 )
EW' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 2.48

Equity to Asset 0.61
EW's Equity to Asset is ranked higher than
68% of the 447 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. EW: 0.61 )
EW' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.74
Current: 0.61

0.37
0.74
Interest Coverage 46.38
EW's Interest Coverage is ranked higher than
60% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 231.38 vs. EW: 46.38 )
EW' s 10-Year Interest Coverage Range
Min: 1.04   Max: 9999.99
Current: 46.38

1.04
9999.99
F-Score: 7
Z-Score: 10.15
M-Score: -3.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) -16.55
EW's Operating margin (%) is ranked higher than
58% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. EW: -16.55 )
EW' s 10-Year Operating margin (%) Range
Min: -29.23   Max: 22.84
Current: -16.55

-29.23
22.84
Net-margin (%) 34.79
EW's Net-margin (%) is ranked higher than
98% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. EW: 34.79 )
EW' s 10-Year Net-margin (%) Range
Min: -33.83   Max: 19.15
Current: 34.79

-33.83
19.15
ROE (%) 46.99
EW's ROE (%) is ranked higher than
99% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. EW: 46.99 )
EW' s 10-Year ROE (%) Range
Min: -32.69   Max: 25.78
Current: 46.99

-32.69
25.78
ROA (%) 26.73
EW's ROA (%) is ranked higher than
99% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. EW: 26.73 )
EW' s 10-Year ROA (%) Range
Min: -21.38   Max: 15.84
Current: 26.73

-21.38
15.84
ROC (Joel Greenblatt) (%) -45.54
EW's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. EW: -45.54 )
EW' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -168.46   Max: 63.32
Current: -45.54

-168.46
63.32
Revenue Growth (3Y)(%) 14.00
EW's Revenue Growth (3Y)(%) is ranked higher than
89% of the 341 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. EW: 14.00 )
EW' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 14
Current: 14

0
14
EBITDA Growth (3Y)(%) 24.00
EW's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. EW: 24.00 )
EW' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 28
Current: 24

0
28
EPS Growth (3Y)(%) 23.40
EW's EPS Growth (3Y)(%) is ranked higher than
89% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. EW: 23.40 )
EW' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 348.1
Current: 23.4

0
348.1
» EW's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

EW Guru Trades in Q4 2013

Pioneer Investments 179,470 sh (New)
Vanguard Health Care Fund 5,324,000 sh (+306.07%)
Joel Greenblatt 117,760 sh (+278.76%)
PRIMECAP Management 280,000 sh (unchged)
Paul Tudor Jones Sold Out
Ray Dalio Sold Out
Jeremy Grantham 67,987 sh (-5.97%)
Ron Baron 1,533,972 sh (-29.66%)
Jim Simons 188,800 sh (-33.03%)
Steven Cohen 3,398 sh (-99.33%)
» More
Q1 2014

EW Guru Trades in Q1 2014

Paul Tudor Jones 101,400 sh (New)
Steven Cohen 13,278 sh (+290.76%)
Pioneer Investments 256,068 sh (+42.68%)
Steven Cohen 150,000 sh (unchged)
PRIMECAP Management 280,000 sh (unchged)
Vanguard Health Care Fund 5,324,000 sh (unchged)
Jim Simons Sold Out
Ron Baron 1,354,511 sh (-11.7%)
Jeremy Grantham 53,446 sh (-21.39%)
Joel Greenblatt 71,689 sh (-39.12%)
» More
Q2 2014

EW Guru Trades in Q2 2014

Jim Simons 19,300 sh (New)
Joel Greenblatt 259,073 sh (+261.38%)
Jeremy Grantham 167,446 sh (+213.3%)
PRIMECAP Management 280,000 sh (unchged)
Vanguard Health Care Fund 4,920,000 sh (-7.59%)
Ron Baron 1,083,004 sh (-20.04%)
Pioneer Investments 203,209 sh (-20.64%)
Paul Tudor Jones 5,000 sh (-95.07%)
» More
Q3 2014

EW Guru Trades in Q3 2014

Steven Cohen 206,300 sh (New)
RS Investment Management 62,460 sh (New)
Paul Tudor Jones 10,112 sh (+102.24%)
Jim Simons 20,900 sh (+8.29%)
Joel Greenblatt 272,994 sh (+5.37%)
PRIMECAP Management 280,000 sh (unchged)
Jeremy Grantham 150,665 sh (-10.02%)
Vanguard Health Care Fund 4,207,470 sh (-14.48%)
Ron Baron 836,867 sh (-22.73%)
Pioneer Investments 144,582 sh (-28.85%)
» More
» Details

Insider Trades

Latest Guru Trades with EW

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-09-30 Reduce -14.48%0.16%$84.44 - $104.02 $ 133.2140%4207470
Ron Baron 2014-09-30 Reduce -22.73%0.08%$84.44 - $104.02 $ 133.2140%836867
Joel Greenblatt 2014-06-30 Add 261.38%0.2%$72.97 - $87.86 $ 133.2164%259073
Ron Baron 2014-06-30 Reduce -20.04%0.08%$72.97 - $87.86 $ 133.2164%1083004
Joel Greenblatt 2014-03-31 Reduce -39.12%0.07%$64.17 - $73.93 $ 133.2193%71689
Vanguard Health Care Fund 2013-12-31 Add 306.07%0.83%$61.44 - $78.14 $ 133.2197%5324000
Ron Baron 2013-12-31 Reduce -29.66%0.21%$61.44 - $78.14 $ 133.2197%1533972
Joel Greenblatt 2013-12-31 Add 278.76%0.13%$61.44 - $78.14 $ 133.2197%117760
Ray Dalio 2013-12-31 Sold Out 0.02%$61.44 - $78.14 $ 133.2197%0
Joel Greenblatt 2013-09-30 Reduce -26.19%0.03%$65.25 - $73.4 $ 133.2190%31091
Ray Dalio 2013-09-30 New Buy0.02%$65.25 - $73.4 $ 133.2190%25695
Ron Baron 2013-06-30 Add 135.69%0.4%$62.54 - $84.93 $ 133.2188%1985766
Meridian Funds 2013-06-30 Add 33.69%0.33%$62.54 - $84.93 $ 133.2188%506700
Vanguard Health Care Fund 2013-06-30 New Buy0.32%$62.54 - $84.93 $ 133.2188%1311100
Joel Greenblatt 2013-06-30 Add 526.16%0.1%$62.54 - $84.93 $ 133.2188%42122
Meridian Funds 2013-03-31 Add 11.14%0.11%$78.66 - $94.56 $ 133.2151%379000
Joel Greenblatt 2013-03-31 Add 35.68%0.01%$78.66 - $94.56 $ 133.2151%6727
Meridian Funds 2012-12-31 Reduce -37.67%0.79%$83.7 - $109.75 $ 133.2148%341000
Ron Baron 2012-12-31 Reduce -20.52%0.15%$83.7 - $109.75 $ 133.2148%828833
Joel Greenblatt 2012-12-31 New Buy0.03%$83.7 - $109.75 $ 133.2148%4958
PRIMECAP Management 2012-09-30 New Buy0.05%$97.37 - $108.72 $ 133.2130%300000
Richard Perry 2012-06-30 Sold Out 0.04%$68.5 - $102.97 $ 133.2158%0
PRIMECAP Management 2012-06-30 Sold Out 0.03%$68.5 - $102.97 $ 133.2158%0
Ron Baron 2012-03-31 Reduce -42.37%0.42%$68.43 - $82.67 $ 133.2192%1228628
Meridian Funds 2012-03-31 Add 52.76%0.41%$68.43 - $82.67 $ 133.2192%564749
Richard Perry 2012-03-31 New Buy0.04%$68.43 - $82.67 $ 133.2192%10700
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.50
EW's P/E(ttm) is ranked higher than
93% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 85.90 vs. EW: 18.50 )
EW' s 10-Year P/E(ttm) Range
Min: 11.15   Max: 3625
Current: 18.5

11.15
3625
P/B 7.00
EW's P/B is ranked higher than
58% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.88 vs. EW: 7.00 )
EW' s 10-Year P/B Range
Min: 2.79   Max: 8.46
Current: 7

2.79
8.46
P/S 6.50
EW's P/S is ranked higher than
61% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.41 vs. EW: 6.50 )
EW' s 10-Year P/S Range
Min: 2.11   Max: 7.38
Current: 6.5

2.11
7.38
PFCF 14.80
EW's PFCF is ranked higher than
95% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 14.80 )
EW' s 10-Year PFCF Range
Min: 7.82   Max: 534.25
Current: 14.8

7.82
534.25
EV-to-EBIT -35.81
EW's EV-to-EBIT is ranked lower than
51% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 64.69 vs. EW: -35.81 )
EW' s 10-Year EV-to-EBIT Range
Min: -35.9   Max: 69.5
Current: -35.81

-35.9
69.5
PEG 1.25
EW's PEG is ranked higher than
97% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 1.25 )
EW' s 10-Year PEG Range
Min: 0.52   Max: 3.5
Current: 1.25

0.52
3.5
Shiller P/E 42.10
EW's Shiller P/E is ranked higher than
88% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 42.10 )
EW' s 10-Year Shiller P/E Range
Min: 25.28   Max: 68.85
Current: 42.1

25.28
68.85
Current Ratio 5.40
EW's Current Ratio is ranked higher than
87% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. EW: 5.40 )
EW' s 10-Year Current Ratio Range
Min: 0.89   Max: 5.4
Current: 5.4

0.89
5.4
Quick Ratio 4.69
EW's Quick Ratio is ranked higher than
87% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. EW: 4.69 )
EW' s 10-Year Quick Ratio Range
Min: 0.49   Max: 4.69
Current: 4.69

0.49
4.69

Valuation & Return

vs
industry
vs
history
Price/Net Cash 68.30
EW's Price/Net Cash is ranked higher than
83% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 68.30 )
EW' s 10-Year Price/Net Cash Range
Min: 52.91   Max: 129.21
Current: 68.3

52.91
129.21
Price/Net Current Asset Value 23.60
EW's Price/Net Current Asset Value is ranked higher than
78% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 23.60 )
EW' s 10-Year Price/Net Current Asset Value Range
Min: 18.29   Max: 309.23
Current: 23.6

18.29
309.23
Price/Tangible Book 8.70
EW's Price/Tangible Book is ranked higher than
64% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.71 vs. EW: 8.70 )
EW' s 10-Year Price/Tangible Book Range
Min: 5.57   Max: 188.29
Current: 8.7

5.57
188.29
Price/DCF (Projected) 2.20
EW's Price/DCF (Projected) is ranked higher than
88% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 2.20 )
EW' s 10-Year Price/DCF (Projected) Range
Min: 1.35   Max: 3.62
Current: 2.2

1.35
3.62
Price/Median PS Value 2.10
EW's Price/Median PS Value is ranked higher than
58% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. EW: 2.10 )
EW' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 2.22
Current: 2.1

0.4
2.22
Price/Peter Lynch Fair Value 0.70
EW's Price/Peter Lynch Fair Value is ranked higher than
100% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 0.70 )
EW' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.57   Max: 3.89
Current: 0.7

0.57
3.89
Price/Graham Number 2.70
EW's Price/Graham Number is ranked higher than
84% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. EW: 2.70 )
EW' s 10-Year Price/Graham Number Range
Min: 1.84   Max: 33.82
Current: 2.7

1.84
33.82
Earnings Yield (Greenblatt) -2.80
EW's Earnings Yield (Greenblatt) is ranked higher than
63% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. EW: -2.80 )
EW' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.8   Max: 7.9
Current: -2.8

-2.8
7.9
Forward Rate of Return (Yacktman) 29.08
EW's Forward Rate of Return (Yacktman) is ranked higher than
95% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 5.50 vs. EW: 29.08 )
EW' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.2   Max: 30
Current: 29.08

3.2
30

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:EWL.Germany,
Edwards Lifesciences Corp was incorporated in Delaware on September 10, 1999. The Company is the manufacturer of heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. It is also a global leader in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. It conducts operations worldwide and are managed in the following geographical regions: United States, Europe, Japan and Rest of World. The products and technologies provided by the Company to treat advanced cardiovascular disease or critically ill patients are categorized into the following main areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care. The Company's Surgical Heart Valve Therapy portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Company's Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. In the Critical Care portfolio, Edwards Lifesciences' products include pulmonary artery catheters, disposable pressure transducers and advanced monitoring systems. The portfolio also includes a line of balloon catheter-based vascular products, surgical clips and inserts. The Company competes with many companies, including divisions of companies much larger than it and smaller companies that compete in specific product lines or certain geographies. The Company's Surgical Heart Valve Therapy and Transcatheter Heart Valve products are manufactured in California and Utah in the United States, Switzerland, and Singapore. Critical Care products are manufactured primarily in its facilities located in Puerto Rico and the Dominican Republic. The Company's products and technologies are subject to regulation by numerous domestic and foreign government agencies, including the FDA, and various laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of its products and technologies.
» More Articles for EW

Headlines

Articles On GuruFocus.com
Edwards Lifesciences a Gold Standard in the Market Dec 16 2014 
East West Petroleum Provides Operational Update Dec 16 2014 
Edwards Lifesciences Invests $50 Million in New Heart Failure Technology Dec 10 2014 
East West Petroleum Announces Drilling of Cheal-E6 Well in New Zealand Nov 26 2014 
East West Petroleum Grants Stock Options Nov 14 2014 
East West Petroleum Provides Operational Update for New Zealand Nov 05 2014 
East West Petroleum Announces Results of Annual General Meeting Oct 15 2014 
EW: Potential for Capital Appreciation Oct 03 2014 
Outperform with Historical Low P/B Portfolios Sep 12 2014 
Weekly 52-Week Highs Highlight: HNP, HDB, MMC, EW Aug 31 2014 


More From Other Websites
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference Dec 19 2014
Edwards Lifesciences a Gold Standard in the Market Dec 16 2014
Why the Earnings Streak Will Continue for Edwards Lifesciences (EW) Dec 12 2014
Credit Suisse Raises 2015 TAVI Estimates for Edwards Lifesciences Corp. Dec 09 2014
Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference Dec 08 2014
Edwards Outlook Near Higher End of Views Dec 08 2014
Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference Dec 08 2014
Luminex Grows on Product Launches & Strategic Partnerships Dec 01 2014
Edwards Lifesciences Strong on Robust Q3, Raised Outlook Nov 28 2014
5 Stock-Moving Medtech Events This December Nov 28 2014
Cramer: Money managers desperate to put $ to work Nov 24 2014
EDWARDS LIFESCIENCES CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Nov 14 2014
Nicholas Valeriani Appointed To Edwards Lifesciences' Board Of Directors Nov 14 2014
Nicholas Valeriani Appointed To Edwards Lifesciences' Board Of Directors Nov 14 2014
Edwards Lifesciences To Present At Credit Suisse 2014 Healthcare Conference Nov 07 2014
Edward Lifesciences 'generating evidence' Nov 07 2014
CEO hopeful for ACA excise tax repeal Nov 07 2014
Medical-Device Stocks Could Benefit From Tax Repeal Nov 05 2014
10-Q for Edwards Lifesciences Corp. Nov 03 2014
EDWARDS LIFESCIENCES CORP Files SEC form 10-Q, Quarterly Report Oct 31 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK